Why the study?
Does telmisartan reduce the progression of diabetic nephropathy compared to valsartan in patients with type 2 diabetes?
Population
More than 800 patients with type 2 diabetes and diabetic nephropathy (associated with proteinuria)
Comparison
Telmisartan vs Valsartan
Follow-up
1 year
Authors
Loading...
Does not change ARB selection in diabetic nephropathy; VIVALDI will test whether telmisartan and valsartan differ in renoprotection or oxidative stress effects.
Does telmisartan reduce the progression of diabetic nephropathy compared to valsartan in patients with type 2 diabetes?
The VIVALDI study is designed to evaluate whether telmisartan reduces the progression of diabetic nephropathy and alters oxidative stress markers compared to valsartan in patients with type 2 diabetes.
Böger et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: